emricasan emricasan emricasan (idn-6556, pf-03491390) is a potential drug invented in 1998 by idun pharmaceuticals. the drug was acquired by pfizer in 2005 and then sold to conatus pharmaceuticals in 2010. conatus in turn licensed emricasan to novartis in 2017 for exclusive development and commercialization. emricasanlegal statuslegal status us: investigational new drug identifiers iupac name (3s)-3-propanoyl]amino}-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid cas number254750-02-2 ypubchem cid12000240chemspider10172707uniip0gms9n47qkeggd10004comptox dashboard (epa)dtxsid10180160 chemical and physical dataformulac26h27f4n3o7molar mass569.501 g·mol−13d model (jsmol)interactive image smiles c(c(=o)n(cc(=o)o)c(=o)coc1c(c(cc(c1f)f)f)f)nc(=o)c(=o)nc2ccccc2c(c)(c)c inchi inchi=1s/c26h27f4n3o7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17h,10-11h2,1-4h3,(h,31,38)(h,32,39)(h,33,37)(h,35,36)/t12-,17-/m0/s1key:scvhjvcatbpihn-sjcjkpomsa-n the substance acts as a pan-caspase inhibitor and has antiapoptotic and antiinflammatory effects. it was developed for the treatment of liver disease and has been granted fast track designation by the fda for the treatment of non-alcoholic steatohepatitis cirrhosis the substance is the first pan-caspase inhibitor to advance to broad clinical testing, and its novel mechanism of action has led to research using it for other potential applications.